Suggested remit: To appraise the clinical and cost effectiveness of epcoritamab within its marketing authorisation for treating relapsed or refractory diffuse large B-cell lymphoma after first-line systemic treatment.
- Status:
- In progress
- Technology type:
- Medicine
- Decision:
- Selected
- Reason for decision:
- Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
- Process:
- STA Standard
- ID number:
- 6463
Provisional Schedule
- Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6463:
- 15 July 2026 - 12 August 2026
Project Team
- Project lead
- scopingta@nice.org.uk
Email enquiries
If you have any queries please email scopingta@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 15 July 2026 | In progress. Scoping commencing |
| 09 December 2025 | Awaiting development. Please note that following on from a request received from the company, the timelines for this appraisal have been revised and the appraisal is now anticipated to begin during early September 2026 when we will write to you about how you can get involved. |
| 12 December 2024 | Referral |
| 25 July 2024 | Topic selection |
| 12 July 2024 | Awaiting development. Status change linked to Topic Selection Decision being set to Selected |
For further information on our processes and methods, please see our CHTE processes and methods manual